

Acta Med. Okayama, 2016  
Vol. 70, No. 4, pp. 299–302

Copyright©2016 by Okayama University Medical School.

Acta Medica  
Okayama

<http://escholarship.lib.okayama-u.ac.jp/amo/>

Clinical Study Protocol

## A Phase II Clinical Trial Evaluating the Preventive Effectiveness of *Lactobacillus* Vaginal Suppositories in Patients with Recurrent Cystitis

Koichiro Wada<sup>a\*</sup>, Shinya Uehara<sup>b</sup>, Ayano Ishii<sup>a</sup>, Takuya Sadahira<sup>a</sup>,  
Masumi Yamamoto<sup>a</sup>, Ritsuko Mitsuhata<sup>a</sup>, Atsushi Takamoto<sup>a</sup>, Motoo Araki<sup>a</sup>,  
Yasuyuki Kobayashi<sup>a</sup>, Masami Watanabe<sup>a</sup>, Toyohiko Watanabe<sup>a</sup>,  
Katsuyuki Hotta<sup>c</sup>, and Yasutomo Nasu<sup>a</sup>

<sup>a</sup>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences,  
and <sup>c</sup>Center for innovative Clinical Medicine, Okayama University Hospital, Okayama 700-8558, Japan,

<sup>b</sup>Department of Urology, Kawasaki Hospital, Kawasaki Medical School, Okayama 700-8505, Japan

Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of *Lactobacillus* vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of *Lactobacillus crispatus* every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.

**Key words:** probiotics, lactobacilli, *Lactobacillus crispatus*, urinary tract infection, vaginal suppository

Urinary tract infections (UTIs) are the most common bacterial infections in women. Most cases of bacterial cystitis can be completely cured using antimicrobial agents recommended by the guidelines of the Japanese Association of Infectious Diseases (JAID) [1]. However, many patients suffer from frequent recurrences of bacterial cystitis, and most clinicians are faced with repeated and long-term administration of broad-spectrum antimicrobial agents. Although urinary abnormalities or underlying urinary tract disease are not usually present, the patient's quality of life is affected and many women become frustrated

by the repeated use of antimicrobial agents. Furthermore, repeated and long-term antimicrobial use leads to the increased presence of drug-resistant bacteria and the disruption of normal levels of intestinal and vaginal flora [2]. Therefore, a new strategy other than administration of antimicrobial prophylaxis against recurrent UTIs in women should be developed.

Reid *et al.* reported several strategies for the prevention of recurrent UTIs. These included the use of probiotics [3], which are defined as living microorganisms that can be administered to promote the health of the host [4] by treating or preventing disease, as an alternative preventative approach. It has

Received June 13, 2016; accepted July 7, 2016.

\*Corresponding author. Phone:+81-86-223-7151; Fax:+81-86-231-3986  
E-mail:gmd17055@s.okadai.jp (K. Wada)

Conflict of Interest Disclosures: No potential conflict of interest relevant to this article was reported.

been reported that the flora of the urogenital tract in patients with recurrent UTIs is abnormal compared with those of healthy women [5-7]. This observation led to the investigation of the role of flora, particularly lactobacilli, in maintaining urogenital health and reducing the risk of infections. The role of *Lactobacillus* in the maintenance of vaginal health was first recognized by Doederlein in the late 18th century [8]. Vaginal lactobacilli protect the female urogenital tract from pathogen colonization and, therefore, can contribute to the prevention of genitourinary tract infection. Many studies have been published describing the relationships between bacterial vaginosis and lactobacilli [9-11] and between lactobacilli and UTIs [3, 12-14]. *L. crispatus* is readily isolated from the vaginas of healthy women [15, 16] and is nearly universal in its abilities to produce hydrogen peroxide, which is toxic to many microorganisms in the vagina, and bind to vaginal epithelial cells [17, 18].

While the effectiveness of *Lactobacillus* vaginal suppositories against recurrent UTIs has been controversial [19, 20], the results of a 2006 clinical study at Okayama University Hospital published by Uehara *et al.* [21] demonstrated the safety of *Lactobacillus* vaginal suppositories and their efficacy against recurrent cystitis. The study was a prospective, single-arm, pilot study, in which *Lactobacillus* vaginal suppositories containing the GAI 98322 strain of *Lactobacillus crispatus* was used. *L. crispatus* GAI 98322 was chosen due to its ability to produce more hydrogen peroxide than other strains of *L. crispatus*. The 9 patients in the 2006 study conducted at Okayama University Hospital demonstrated that vaginal suppositories containing *L. crispatus* could significantly reduce UTI recurrence without complications during treatment. Furthermore, Ann *et al.* reported on a randomized control trial of *L. crispatus* vaginal suppositories, with results supporting their preventative efficacy against recurrent urinary tract infections [22].

The present study is a larger phase II, single-arm clinical trial to evaluate preventive effectiveness and safety of *Lactobacillus* vaginal suppositories in patients with frequently recurrent cystitis.

### Endpoints

The primary endpoint in this trial is recurrence of a cystitis which requires administration of antimicro-

bial agents. Cystitis consists of pyuria, bacteriuria and symptoms. Pyuria is defined as  $\geq 10$  white blood cells (WBCs)/ $\mu\text{L}$  as determined by flow cytometric analysis;  $\geq 10$  WBCs/ $\text{mm}^3$  as counted using a counting chamber or as indicated by a positive leucocyte esterase result using a urine test strip with uncentrifuged urine; or  $> 5$  WBCs/high power field (hpf) in the sediment of centrifuged urine. Bacteriuria is defined as catheter urine containing  $\geq 10^4$  CFU (colony-forming units) /mL of live bacteria or midstream urine containing  $\geq 10^5$  CFU/mL. Symptoms include micturition pain, urinary frequency/urgency, or lower abdominal pain. Participants with asymptomatic pyuria and bacteriuria are not diagnosed as recurrent UTI.

During the administrations of antimicrobial agents against recurrent UTIs, administration of vaginal suppositories should be continued for 1 year to count the number of recurrences.

Secondary endpoints are adverse events due to the suppository and changes in isolated vaginal bacterial strains monthly examined by culture of vaginal swabs.

### Eligibility Criteria

Adult (less than 80 years old) female outpatients with 2 or more episodes of uncomplicated/complicated cystitis within the past year can be enrolled. However, the UTI must be treated and cured at entry. Complicated cystitis includes the crisis of chronic cystitis in patients performing clean intermittent self-catheterization (CISC) and in patients with mild underlying diseases in their urinary tract such as overactive bladder (OAB) and neurogenic bladder (NGB) with 50ml or less of residual urine volume after urination. Exclusion criteria include: the presence of underlying urological diseases for which a urological procedure is necessary; continuous urethral catheterization; uncontrollable and severe diseases such as diabetes mellitus (DM), collagen diseases, advanced malignancies, and heart/liver/kidney dysfunctions; allergy to dairy products or fermented dairy products; and low compliance, as assessed by the investigators.

### Treatment Methods

In this phase II study, patients with acute uncomplicated/complicated cystitis will be recruited between

December 2013 and March 2018 at the Urology outpatient clinic in Okayama University Hospital.

**Lactobacillus strains.** *Lactobacillus crispatus* GAI 98322 is used in this study because 1) it had already been isolated from the vaginas of healthy women and 2) a quantitative hydrogen peroxide assay performed in the pilot study determined that GAI 98322 had the highest capacity for hydrogen peroxide production of 3 strains of *L. crispatus* (GAI 98322, GAI 99098, and GAI 99099) provided by K. Watanabe (Division of Anaerobe Research, Life Science Research Center, Gifu University, Japan).

**Vaginal suppositories.** *Lactobacillus* vaginal suppositories containing *L. crispatus* GAI 98322 at  $1.0 \times 10^8$  CFU per suppository, are made, following a viability assay, at the Pharmacy in Okayama University Hospital using the same method as Uehara *et al.* [21].

**Protocol.** Patients without cystitis at entry into this trial are instructed to insert a vaginal suppository containing *L. crispatus* GAI 98322 every 2 days or 3 times a week for 1 year before going to bed. This regimen is used in the pilot study reported by Uehara *et al.* [21]. The patients visit our hospital every month for an examination of subjective symptoms. Urinalysis and culturing of urine and vaginal discharge are also performed. UTI incidence and vaginal bacterial colonization before and during administration of vaginal suppositories are compared. If there is evidence of a recurrence of UTI as mentioned above, an antimicrobial agent is simultaneously given with the vaginal suppository.

### Statistical Consideration

In our outpatient clinic, around 20 patients a year undergo treatment against uncomplicated/complicated cystitis via antimicrobial agents each year. On average, almost 50% of the patients, especially with complicated cystitis, experience recurrence of cystitis. We anticipate that 5 or 6 patients with consent will be enrolled in this study each year. Thus, a total of 20 patients will be included in this trial held within 5 years. The data is analyzed using JMP software (ver. 11; SAS, Cary, NC, USA) and  $p < 0.05$  is considered to be statistically significant. According to first recurrence during the study, mean and 50% recurrence-free survival are evaluated by the Kaplan-

Meier method. The data regarding to the number of recurrence during this study are analyzed using Mann-Whitney's exact test compared with those before administration of vaginal suppositories, and the data of the number of recurrence are analyzed according to age, menopausal or premenopausal, kinds of pathogens and presence of underlying diseases in their urinary tract (complicated or uncomplicated). Furthermore, recurrence rate by definition of cystitis including pyuria, bacteriuria and symptoms are evaluated using Chi-squared test. Adverse events are assessed by Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0 and relationship between severity and administration duration is analyzed.

### Ethics

This clinical study was approved by the Okayama University Institutional Review Board prior to study initiation (Registration no. m14008). The study was registered with the UMIN Clinical Trials Registry (UMIN-CTR), Japan (UMIN000015476). Participants reviewed the informed consent document and received individual counseling with a thorough discussion as to alternative treatment, including nonparticipation.

**Acknowledgments.** This work is supported by a Grant-in-Aid for Scientific Research C (2013–2016, No. 25462514) from the Japan Society for the Promotion of Science.

### References

1. JAID/JSC Guide to Clinical Management of Infectious Diseases Committee eds.: The JAID/JSC Guide to Clinical Management of Infectious Diseases Committee: XI Urogenital infections. Life Science Publishing Co., Ltd., Tokyo, p.203–228, (2014).
2. Reid G, Bruce AW, Cook RL and Llano M: Effect on urogenital flora of antibiotic therapy for urinary tract infection. *Scand J Infect Dis* (1990) 22: 43–47.
3. Reid G: Potential preventive strategies and therapies in urinary tract infection. *World J Urol* (1999) 17: 359–363.
4. Scott KP, Antoine JM, Midtvedt T and van Hemert S: Manipulating the gut microbiota to maintain health and treat disease. *Microb Ecol Health Dis* (2015) 26: 25877.
5. Stamey TA: The role of introital enterobacteria in recurrent urinary infections. *J Urol* (1973) 109: 467–472.
6. Schaeffer AJ and Stamey TA: Studies of introital colonization in women with recurrent urinary infections. IX. The role of antimicrobial therapy. *J Urol* (1977) 118: 221–224.
7. Seddon JM, Bruce AW, Chadwick P and Carter D: Introital bacterial flora -effect of increased frequency of micturition. *Br J Urol* (1976) 48: 221–228.
8. Butler BC and Beakley JW: Bacterial flora in vaginitis: a study

- before and after treatment with pure cultures of Doederlein bacillus. *Am J Obstet Gynecol* (1960) 79: 432-440.
9. Reid G, Beuerman D, Heinemann C and Bruce AW: Probiotic *Lactobacillus* dose required to restore and maintain a normal vaginal flora. *FEMS Immunol Med Microbiol* (2001) 32: 37-41.
  10. Reid G and Burton J: Use of *Lactobacillus* to prevent infection by pathogenic bacteria. *Microbes Infect* (2002) 4: 319-324.
  11. Reid G, Howard J and Gan BS: Can bacterial interference prevent infection? *Trends Microbiol* (2001) 9: 424-428.
  12. Reid G, Chan RC, Bruce AW and Costerton JW: Prevention of urinary tract infection in rats with an indigenous *Lactobacillus casei* strain. *Infect Immun* (1985) 49: 320-324.
  13. Reid G, Bruce AW, Fraser N, Heinemann C, Owen J and Henning B: Oral probiotics can resolve urogenital infections. *FEMS Immunol Med Microbiol* (2001) 30: 49-52.
  14. Reid G: Probiotic agents to protect the urogenital tract against infection. *Am J Clin Nutr* (2001) 73 (Suppl. 2): S437-443.
  15. Antonio MA, Hawes SE and Hillier SL: The identification of vaginal *Lactobacillus* species and the demographic and microbiologic characteristics of women colonized by these species. *J Infect Dis* (1999) 180: 1950-1956.
  16. Bonadio M, Meini M, Spitaleri P and Gigli C: Current microbiological and clinical aspects of urinary tract infections. *Eur Urol* (2001) 40: 439-444.
  17. Eschenbach DA, Davick PR, Williams BL, Klebanoff SJ, Young-Smith K, Critchlow CM and Holmes KK: Prevalence of hydrogen peroxide-producing *Lactobacillus* species in normal women and women with bacterial vaginosis. *J Clin Microbiol* (1989) 27: 251-256.
  18. Beigi RH, Wiesenfeld HC, Hillier SL, Straw T and Krohn MA: Factors associated with absence of H<sub>2</sub>O<sub>2</sub>-producing *Lactobacillus* among women with bacterial vaginosis. *J Infect Dis* (2005) 191: 924-929.
  19. Reid G, Bruce AW and Taylor M: Influence of three-day antimicrobial therapy and *Lactobacillus* vaginal suppositories on recurrence of urinary tract infections. *Clin Ther* (1992) 14: 11-16.
  20. Baerheim A, Larsen E and Digranes A: Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. *Scand J Prim Health Care* (1994) 12: 239-243.
  21. Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R and Kumon H: A pilot study evaluating the safety and effectiveness of *Lactobacillus* vaginal suppositories in patients with recurrent urinary tract infection. *Int J Antimicrob Agents* (2006) 28 (Suppl 1): S30-34.
  22. Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M and Stamm WE: Randomized, Placebo-Controlled Phase 2 Trial of a *Lactobacillus crispatus* Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract Infection. *Clin Infect Dis* (2011) 52: 1212-1217.